Editing Glaucoma (section)

==Research==
[[File:Exploring-Eye-Movements-in-Patients-with-Glaucoma-When-Viewing-a-Driving-Scene-pone.0009710.s001.ogv|thumb|right|Scientists track eye movements in glaucoma patients to check vision impairment while driving.]]

=== Eye drops vs. other treatments ===
The TAGS randomised controlled trial investigated if eye drops or trabeculectomy is more effective in treating advanced primary open-angle glaucoma. After two years researchers found that vision and quality of life are similar in both treatments. At the same time eye pressure was lower in people who underwent surgery and in the long-run surgery is more cost-effective.<ref>{{Cite journal |date=2022-03-31 |title=Advanced glaucoma: surgery lowers pressure in the eye more effectively than eye drops |url=https://evidence.nihr.ac.uk/alert/advanced-glaucoma-surgery-is-effective/ |journal=NIHR Evidence |type=Plain English summary |language=en |publisher=National Institute for Health and Care Research |doi=10.3310/alert_49606|s2cid=247918434 }}</ref><ref>{{cite journal | vauthors = King AJ, Fernie G, Hudson J, Kernohan A, Azuara-Blanco A, Burr J, Homer T, Shabaninejad H, Sparrow JM, Garway-Heath D, Barton K, Norrie J, McDonald A, Vale L, MacLennan G | display-authors = 6 | title = Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma: TAGS RCT | journal = Health Technology Assessment | volume = 25 | issue = 72 | pages = 1–158 | date = November 2021 | pmid = 34854808 | doi = 10.3310/hta25720 | doi-access = free | hdl = 2164/18078 | hdl-access = free }}</ref>

The LiGHT trial compared the effectiveness of eye drops and selective laser trabeculoplasty for open angle glaucoma. Both contributed to a similar quality of life but most people undergoing laser treatment were able to stop using eye drops. Laser trabeculoplasty was also shown to be more cost-effective.<ref name="Gazzard_2019">{{cite journal | vauthors = Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Buszewicz M | display-authors = 6 | title = Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial | journal = Lancet | volume = 393 | issue = 10180 | pages = 1505–1516 | date = April 2019 | pmid = 30862377 | pmc = 6495367 | doi = 10.1016/S0140-6736(18)32213-X }}; {{lay source |template=cite web |date= 4 June 2019 |title=A laser eye procedure can be effective and safe if used early as treatment for glaucoma |url=https://evidence.nihr.ac.uk/alert/a-laser-eye-procedure-can-be-effective-and-safe-if-used-early-as-treatment-for-glaucoma | work =NIHR Evidence |quote = Plain English summary |publisher=National Institute for Health and Care Research |doi=10.3310/signal-000774 }}</ref>

===Comparison of effects of brimonidine and timolol===
A 2013 [[Cochrane Collaboration|Cochrane systematic review]] compared the effect of brimonidine and timolol in slowing the progression of open angle glaucoma in adult participants.<ref name="Sena">{{cite journal | vauthors = Sena DF, Lindsley K | title = Neuroprotection for treatment of glaucoma in adults | journal = The Cochrane Database of Systematic Reviews | volume = 1 | pages = CD006539 | date = January 2017 | issue = 1 | pmid = 28122126 | pmc = 5370094 | doi = 10.1002/14651858.CD006539.pub4 }}</ref> The results showed that participants assigned to brimonidine showed less visual field progression than those assigned to timolol, though the results were not significant, given the heavy [[Lost to follow-up|loss-to-followup]] and limited evidence.<ref name=Sena/> The mean intraocular pressures for both groups were similar. Participants in the brimonidine group had a higher occurrence of side effects caused by medication than participants in the timolol group.<ref name=Sena/>